Olr232 inhibitors represent a specialized class of chemical compounds designed to specifically interact with and inhibit the activity of the Olr232 protein, a member of the olfactory receptor family. These receptors are G protein-coupled receptors (GPCRs) primarily expressed in the olfactory epithelium, where they play a key role in the detection of odorants. The Olr232 protein, encoded by the Olr232 gene, is part of the largest gene family in the mammalian genome, which is involved in the initial steps of the olfactory signal transduction pathway. Olr232 inhibitors are designed to bind selectively to this receptor, effectively blocking the interaction between Olr232 and its endogenous ligands, which could include specific odorant molecules. The specificity of these inhibitors is paramount, as it ensures that the inhibition is targeted and does not affect the function of other olfactory receptors or GPCRs, thereby minimizing off-target effects in research settings.
In the context of molecular biology and biochemistry, Olr232 inhibitors are valuable tools for probing the function and signaling pathways associated with this specific olfactory receptor. By inhibiting Olr232, researchers can dissect the role of this receptor in olfactory perception and better understand the downstream signaling cascades that are triggered by its activation. Additionally, the development and application of these inhibitors can aid in the identification of the natural ligands of Olr232, thereby contributing to the broader understanding of olfactory receptor-ligand interactions. Moreover, these inhibitors can be utilized in structural biology studies to elucidate the conformational changes that Olr232 undergoes upon ligand binding and during inhibition, providing deeper insights into the structural dynamics of GPCRs. The ongoing study of Olr232 inhibitors not only expands our understanding of olfactory signaling but also enriches the broader field of GPCR research, offering new perspectives on receptor-ligand interactions and inhibition mechanisms.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
RAF kinase inhibitor, potentially disrupts cell signaling pathways Olr232 may be part of. | ||||||
Zanubrutinib | 1691249-45-2 | sc-507434 | 5 mg | $360.00 | ||
Bruton’s tyrosine kinase inhibitor, could modulate B-cell receptor signaling affecting Olr232. | ||||||
BYL719 | 1217486-61-7 | sc-391001 sc-391001A sc-391001B sc-391001C sc-391001D sc-391001E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $383.00 $585.00 $740.00 $1169.00 $4902.00 $9186.00 | 2 | |
PI3K inhibitor, may impact signaling pathways involved in cell growth and survival related to Olr232. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
BCL-2 inhibitor, possibly influences apoptosis pathways potentially linked to Olr232's function. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Dual EGFR and HER2 inhibitor, could disrupt growth factor signaling pathways involving Olr232. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Multi-targeted receptor tyrosine kinase inhibitor, might affect angiogenesis and other pathways Olr232 is involved in. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
mTOR inhibitor, can modulate cell growth and proliferation pathways potentially involving Olr232. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Multi-kinase inhibitor, potentially impacts several signaling pathways relevant to Olr232. | ||||||
Rucaparib | 283173-50-2 | sc-507419 | 5 mg | $150.00 | ||
PARP inhibitor, might affect DNA repair mechanisms and pathways linked to Olr232. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
MET and VEGFR2 inhibitor, could impact angiogenesis and cell survival pathways related to Olr232. | ||||||